Ambulatory Withdrawal Management Greg Sutmiller MS, LPC, LADC.

Slides:



Advertisements
Similar presentations
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Advertisements

13 Principles of Effective Addictions Treatment
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Outpatient Treatment Ellen A. Ovson, M.D. Medical Director
Swinomish Wellness Program
Colorado Department of Healthcare Policy and FinancingColorado Department of Healthcare Policy and Financing Improving health care access and outcomes.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
JANUARY 2013 SUBSTANCE ABUSE TREATMENTBASICS. WHY DO PEOPLE USE DRUGS AND ALCOHOL? People use substances such as alcohol and other drugs because they.
MEDICATION ASSISTED TREATMENT for OPIATE DEPENDENCY WHAT WORKS? SHELLEY ASKEW FLOYD, MS DIRECTOR OF PHARMACOTHERAPY SERVICES PYRAMID HEALTHCARE, INC.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Ken Saffier, MD, Natasha Pinto, MD And Patients CCRMC/HC Noon Conference February 18, 2010.
The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
Opioid Dependence in Missouri Cheryl Marcum, Missouri State Opioid Treatment Authority AATOD 2015.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, MA Deputy Director 1.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, MA Deputy Director 2/23/20151.
Module V: Coordinated Care BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006
Buprenorphine Therapy in Primary Care: One Prescriber’s Experience Pittsburgh, PA August 24, 2005 Melinda Campopiano, M.D. Baron Edmond de Rothschild Chemical.
Module V – Coordinated Care BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment.
Module 1 General introduction to substitution treatment.
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
The Counseling Center, Inc. Devoted to the prevention and treatment of alcoholism and other drug addictions. We promote opportunities for individuals and.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
BUPRENORPHINE TREATMENT: A Training For Addiction Professionals BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module.
Opiate Management Douglas Keehn DO Adjunct Assistant Clinical Professor University Wisconsin Board Certified Anesthesia & Pain Management.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
Prevention, Identification and Treatment of Opioid Use Disorders: A Personal Perspective Leah Bauer, MD Medical Director, Addiction Resource Center, Mid.
Buprenorphine {Suboxone®, Subutex®}
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Buprenorphine Daryl Shorter, MD Michael E. DeBakey VA Medical Center Menninger Department of Psychiatry and Behavioral Science Baylor College of Medicine.
Medicated Assisted Treatment (MAT) Terry R. Jones Director of Behavioral Health.
FAMILY RECOVERY NETWORK EVENT: What is Substance Abuse Treatment? Patrick Seche, MS, CASAC Strong Recovery Addiction Psychiatry Division Department of.
1 Use of Pharmacotherapies by Substance Abuse Treatment Facilities November 2007 Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration.
Medstat MercuryMD Micromedex PDR Solucient Substance abuse medications: Trends and prescribing patterns by physician specialty November 5, 2007 American.
Benjamin J. Pariser, DO RASE Physician.  This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery.
Medication Assisted Treatment for Opioid Use Disorders
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Responding to the Opioid Addiction Epidemic Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians for.
Gregory S. Brigham, Ph.D., CEO
Medical Assisted Treatment
Medication Assisted Treatment
Medication Assisted Treatment

Levels of Care Continuum of Care ASAM Patient Placement Criteria (PPC)
Opioid Medication Assisted Tx (1)
Medication-Assisted Therapy at Coleman Profession Services
Methadone and Suboxone
Opioids – A Pharmaceutical Perspective on Prescription Drugs
CLINICAL INTRO TO: OPIOID ABUSE AMONGST PEOPLE EXPERIENCING HOMELESSNESS TYLER GRAY, MD HEALTHCARE FOR THE HOMELESS, BALTIMORE, MD.
MEDICATION ASSISTED TREATMENT for OPIATE ADDICTION
Medication assisted treatment
Medication-Assisted Treatment 101: Breaking the Stigma
Barbara Allison-Bryan, MD
Pain Management: Patients Maintained on Buprenorphine
Medication-assisted treatment for opioid use disorder John e lopes jr
Michael C. White, MCJ
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
A Training For Multidisciplinary Addiction Professionals
Are you sick and tired of being sick and tired?
Medications used in Treatment of Alcohol and Drug Use Disorders
Medically assisted treatment
Medication Assisted Treatment of Opioid Use Disorder
Opiate misuse among our seniors
Treat Opioid USE DISORDER like the chronic disease it is
Presentation transcript:

Ambulatory Withdrawal Management Greg Sutmiller MS, LPC, LADC

What is it? Ambulatory Detoxification & more SAMHSA: outpatient treatment services providing for safe withdrawal in an ambulatory setting - Managing acute and post-acute withdrawal symptoms in an outpatient setting.

Why is it needed? “Opiates are outranked only by alcohol as humanity’s oldest, most widespread, and most persistent drug problem.” Harvard Mental Health Letter, 2004 Dr. Leo Kadehjian

Why is it needed? Drug Overdose (OD): 2nd leading cause of unintentional deaths after motor vehicle fatalities CDC, 2010 Opioids: 93% of prescription OD deaths JAMA 2008 Prescription OD deaths increased x4 since 1999 (>heroin + cocaine combined) CDC, 2013 Heroin OD deaths +45% 2006–2010 SAMHSA, 2013 Dr. Leo Kadehjian

Why is it needed? United States’ Drug Consumption 4.6% of world population Consumes 2/3 of illicit drug supply Consumes 80% of global opioid supply Consumes 99% of global hydrocodone supply L. Manchikanti and A. Singh, 2008 Dr. Leo Kadehjian

Why is it needed? Oxycodone per Capita DEA 2013 Oxycodone Production Quota: 135,000 kg 2011 U.S. Population: 311,591, ,000 kg / 311,591,917 persons = 422 mg/person! Dr. Leo Kadehjian

Why is it needed? Tolerance builds up significantly and quickly. Tolerated dose can increase 10x in as little as two weeks and up to 35x ultimately. Opiate drugs are becoming more potent. OxyContin Heroin 60%-80% currently vs. 10% or less in 1970’s More people are abusing opiates and becoming opiate dependent. The age of initiation is getting lower. Baby boomers are becoming dependent. Steve Hanson

Why is it needed?

Lots of people are opiate dependent! Lots of people need to get off opiates! What happens when opiate dependent people come off opiates?

Why is it needed?

Key Component #4 “Drug courts provide access to a continuum of alcohol, drug, and other related treatment rehabilitation services.” Includes detoxification

Why is it needed? NADCP Best Practice Standards Part of the continuum of care Determined by standardized assessment (not phase or professional judgment) ASAM-PPC Participants cannot be sanctioned for substance use if they are at a lower level of care than they need.

Why is it needed? ASAM Least Restrictive Level I-D: Ambulatory Detoxification Without Extended Onsite Monitoring Level II-D: Ambulatory Detoxification With Extended Onsite Monitoring Requires specific medical staff: RN/LPN, PA, NP, Physician Requires daily monitoring

Who’s it for? Alcohol and Opiates Focus on Opiate Withdrawal Opiate Dependent Mild to Moderate Withdrawal Symptoms COWS ASAM Dimensions Assessment Driven

Who’s it for? COWS

What’s the goal? Stabilization Manage Withdrawal Symptoms Eliminate Illicit Opiate Use

What’s the goal? Get Started Feel better Engage in treatment Manage responsibilities

What’s the process? Regular Office Visits Every few days to every day based on need ASAM Level I-D ASAM Level II-D Check in Vital signs Assessment Medication Drug Screens Therapy and/or other psychosocial services

What’s the process? Assessment COWS Physical Psychological Case Management

What’s the process? Medication Managing Symptoms Clonidine, nausea & diarrhea meds, hypertension meds, etc. Full Agonist Methadone Partial Agonist Buprenorphine (Subutex) Partial Agonist w/ Antagonist Buprenorphine-Naloxone (Suboxone) Full Antagonist Naltrexone (Revia, Depade, Vivitrol)

What’s the process? Medically Assisted Treatment (MAT) NADCP Best Practice Standards “Participants are prescribed psychotropic or addiction medications based on medical necessity as determined by a treating physician with expertise in addiction psychiatry, addiction medicine, or a closely related field.” MAT can… Improve outcomes Increase engagement in treatment Reduce illicit drug use Reduce other program violations

What’s the process? Buprenorphine and Medically Supervised Withdrawal BUP can be used to cease opiate use or to transition out of agonist (methadone) treatment. Cease opiate use Withdrawal symptoms present 1-2 initial doses on first day Build up dose over next couple days Make sure consumer is compliant and stable Reduction of dose over next few days Some consumers may need to take longer in reduction phase or enter maintenance treatment

What’s the process? Drug Screens Screen for the Standards Screen for Specific Opiates Screen for Metabolites

What’s the process? Therapy and Other Psychosocial Services VITAL Outpatient (ASAM Level I) Intensive Outpatient (ASAM Level II) Daily if necessary Individual, Group, Case Management, Recovery Support Coordination is key!

What does a specialty court need to consider? Coordination Communication Team members Other service providers Adequate Team Representation Medical professional(s) Innovation Creativity Caution

References Hallford, J. (2014, July 25). Personal interview. addiction/section-iii-action-heroin-morphine/10-addiction-vs-dependence addiction/section-iii-action-heroin-morphine/10-addiction-vs-dependence National Association of Drug Court Professionals. Adult Drug Court Best Practice Standards: Volume I. 2013, Alexandria, VA. Substance Abuse and Mental Health Services Administration. TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004, Rockville, MD. Substance Abuse and Mental Health Services Administration. TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. 2005, Rockville, MD.

Contact Greg Sutmiller (918)